Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Discover
Back to filter
Show all topics (10)
Related topics
Curiox webinar - how to retain more cells for Single Cell Sequencing and proteogenomics ?
Feb 15, 2021
Curiox Laminar Wash technology has been added as part of the official BioLegend TotalSeq...
Cytek Aurora in Action : how to easily resolve highly overlapping dyes ?
Feb 2, 2021
Learn from Jeff Nelson, a manager of a cytometry shared resource laboratory, about the...
Webinar: A simple Migration/Invasion workflow using IncuCyte Live-cell analysis system
Jan 27, 2021
Cell migration and invasion, or cell motility, play a role in many normal and...
Webinar : meet the Cytek's new cFluor reagents
Jan 25, 2021
Cytek Biosciences has already redefined what is possible in flow cytometry. The new Cytek...
Introducing Cytek cFluor, 14 Colors Immunoprofiling Kit
Jan 19, 2021
Cytek cFluor Immunoprofiling Kit allows for the identification of helper T cells,...
Cytek full Spectrum flow Cytometry webinar: Part II – panel design and troubleshooting
Jan 11, 2021
In this session, we will continue to look at full spectrum flow cytometry and look at considerations for fluorescence...
IncuCyte for in-vitro analysis of SARS-CoV-2 vaccine candidate
Jan 4, 2021
Watch this video to learn how researcher at Humane Genomics are utilizing the Incucyte...
Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
Dec 29, 2020
Radio-active sources have been used routinely for the preconditioning in humanized mouse...
Advances in Leukemia research using shear flow and Bioflux system
Dec 10, 2020
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes...
Do you have our CellRad benchtop irradiator? It’s the only one on the market!
Dec 9, 2020
The CellRad is a smaller, simpler, safer, and more cost effective alternative to...
Preclinical PET imaging in studies of candidate therapeutics
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Brand profile
